UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48% — Barrons.com

By Mackenzie TatananniUniQure stock plunged on Tuesday after the drugmaker issued a disappointing update regarding its closely watched candidate for Huntington's disease.Amsterdam-based uniQure reported that its experimental gene therapy for Huntington's disease fell short in a recent study. In the…